文章摘要

文章信息/Info

Title:: Effects of Atorvastatin combined with Rosiglitazone on hsCRP in patients with unstable angina and Ⅱ type diabetes mellitus

作者:: 蒋路平 ; 周胜华; 中南大学湘雅二医院心内科，湖南长沙 410011

Author(s):: JIANG Luping; ZHOU Shenghua; Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

关键词:: 阿托伐他汀; 罗格列酮; 不稳定型心绞痛; 高敏C反应蛋白; 糖尿病; Ⅱ型

Keywords:: atorvastatin ; rosiglitazone ; unstable angina ; high sensitivity Creactive protein; diabetes mellitus; Ⅱ type

分类号:: R329.26

DOI:: -

文献标识码:: A

摘要:: 目的探讨阿托伐他汀联合罗格列酮对不稳型心绞痛并Ⅱ型糖尿病患者高敏C反应蛋白（High sensitivity Creactive protein，hsCRP）的影响。方法 96例不稳定型心绞痛并Ⅱ型糖尿病患者随机分成4组，对照组22例，采用常规的抗凝、扩张冠状动脉及降糖治疗；阿托伐他汀组23例，在常规治疗的基础上加用阿托伐他汀10 mg/d；罗格列酮组25例，在常规治疗的基础上加用罗格列酮4 mg/d；阿托伐他汀、罗格列酮联合治疗组26例，除常规治疗外，联合使用阿托伐他汀10 mg/d和罗格列酮4 mg/d。用颗粒增强免疫透射比浊法测定治疗前后血清hsCRP。结果与对照组比较阿托伐他汀和罗格列酮均可使血hsCRP降低（P<0.05），阿托伐他汀、罗格列酮联合治疗组血hsCRP下降更显著（P<0.01）; 阿托伐他汀、罗格列酮联合治疗降hsCRP的效果优于单用阿托伐他汀或罗格列酮（P<0.05）。结论联合使用阿托伐他汀和罗格列酮可使hsCRP下降更显著。

Abstract:: AIM To investigate the effects of Atorvastatin combined with Rosiglitazone on hsCRP in patients with unstable angina and Ⅱ type diabetes mellitus. METHODS Ninety six patients with unstable angina and diabetes mellitus were treated with conventional therapy or plus Atorvastatin (10 mg/d) or plus Rosiglitazone(4 mg/d) or with the combination of Atorvastatin (10 mg/d) and Rosiglitazone 4 mg/d). The serum high sensitivity Creactive protein (hsCRP ) was measured before and after the treatment by particle enhanced immunoturbidimetric assay. RESULTS Compared with that in control, the serum hsCRP decreased by the treatment with Atorvastatin or Rosiglitazone respectively（P<0.05）and was markedly lower in the group treated by Atorvastatin combined with Rosiglitazone（P<0.01）. The combination of Atorvastatin and Rosiglitazone had better effects on lowing hsCRP（P<0.05）than Atorvastatin or Rosiglitazone alone. CONCLUSION Treatment with the combination of Atorvastatin and Rosiglitazone has the best effects on lowering hsCRP.

参考文献/References

［1］ Burke AP, Tracy RP, Kolodgie F, et al. Elevated Creactive protein values and therosclerosis in sudden coronary death: association with different pathologies［J］. Circulation,2002,105（17）:2019-2023.

［2］ Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy［J］. Curr Med Res Opin , 2003, 19（6）:540-556.

［3］ LlorenteCortes V, MartinezGonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth cells is reduced by HMGCOA reductase inhibitors ［J］. Arterioscler Thromb Vasc Biol,1998,18（5）:738-746.

［4］ Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferatoractivated receptors and atherogensis：regulators of gene expression in vascular cells ［J］. Circ Res ,2004,94（9）:1168-1178.

［5］ Chu CS, Lee KT, Lee MY ,et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with 2 diabetes mellitus［J］. Am J Cardiol ，2006,97(5):646-650.

我们的网站为什么显示成这样？

阿托伐他汀联合罗格列酮对不稳定型心绞痛并发Ⅱ型糖尿病患者高敏C反应蛋白的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics